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bstract
The reverse phase high performance liquid chromatographic (RP-HPLC) method has been developed for simultaneous esti-
ation of starting material, impurities and final product in bulk API forms. The proposed method utilizes waters symmetry C18
250 cm ×  4.6 mm, 5 m) column, mobile phase consisting of buffer and acetonitrile in the proportion of 40:60 (v/v) with apparent
H adjusted to 3.2, and UV detection at 245 nm. The described method was linear (r2 ≥  0.99) over a range of 1–50 g/mL and
elative standard deviation values for intra-day and inter-day precision studies were less than 1.0% for all ingredients. The analytical
ean recoveries of salicylic acid, salicylamide and deferasirox by the developed RP-HPLC method were 99.74%, 99.52% and
9.40% respectively. This method was validated by evaluation of different parameters like specificity, accuracy, precision, system
uitability, linearity, LOD and LOQ according to ICH guidelines. The method has been successfully applied for the analysis of
rugs in pharmaceutical dosages forms.
 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
licylic aeywords: Rp-HPLC; Simultaneous determination; Salicylamide; Sa
.  Introduction
Deferasirox [4-[(3Z, 5E)-3,5-bis(6-oxo-1-cyclohexa-
,4-dienylidene)-1,2,4-triazolidin-1-yl] benzoic acid [1]
s an orally active chelator that is highly selective for
ron (III). It is a tridentate ligand that binds iron with
igh affinity in a 2:1 ratio [2]. It is listed in the Merck
ndex 14th edition [3]. Deferasirox (EXJADE) has been∗ Corresponding author. Tel.: +91 9825209177.
E-mail address: dnisheeth@rediffmail.com (N.C. Desai).
eer review under responsibility of Taibah University.
ttp://dx.doi.org/10.1016/j.jtusci.2014.11.006
658-3655 © 2014 The Authors. Production and hosting by Elsevier B.V. on 
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).cid; Deferasirox
investigated in adult and pediatric patients (aged 2 years
and older) with chronic iron overload due to blood trans-
fusions. Deferasirox is used to remove excess iron from
the body after a person has too many blood transfu-
sions. The underlying conditions requiring transfusion
included beta-thalassaemia, sickle cell disease and other
congenital and acquired anaemias (myelodysplastic syn-
dromes, Diamond-Blackfan syndrome, aplastic anemia)
and in patients with non-transfusion-dependent tha-
lassemia syndromes. In order to develop a new precise
method there is an immense need for developing a rapid,
sensitive and validated analytical method for day-to-day
analysis, in routine analysis in quality control labora-behalf of Taibah University. This is an open access article under the
tories of the drug and which can be even applicable
for pharmaceutical dosage forms [4]. Few LC meth-
ods for determination of deferasirox were reported in
ibah Un
final chromatographic conditions. Deferasirox is soluble
in methanol and acetonitrile–water mixture. The peak
shapes, resolution and symmetry of salicylamide, sali-
cylic acid and deferasirox were good with above gradient
elution at a 1.0 mL/min flow rate. The method devel-246 N.C. Desai, R.D. Senta / Journal of Ta
the literature review [5–8] and some reports mainly
included the determination of deferasirox in biological
fluids [9,10], Terbium-sensitized fluorescence method
for determination of deferasirox in biological fluids and
tablet formulation [11]. Deferasirox promotes excre-
tion of iron, primarily in the feces. Two molecules of
Deferasirox combine with iron in the blood and then
removed from the body by the kidneys [12,13].
Salicylamide (SAL), 2-hydroxybenzamide is a
salicylic acid derivative that has analgesic, anti-
inflammatory and antipyretic actions. It is used for pain,
fever and inflammatory disorders such as osteoarthri-
tis and rheumatoid arthritis [14]. The USP [15]
recommended non-aqueous titration method for the
determination of SAL in raw material using sodium
methoxide as a titrant and thymol blue as indicator.
Several analytical methods are described for the determi-
nation of SAL, whether in dosage forms or in biological
fluids. Such methods include; spectrophotometry [16],
spectrofluorimetry [17,18], HPTLC [19], HPLC [20].
Salicylic acid (SA) is keratolytic in nature and chem-
ically 2-hydroxy benzoic acid [21]. Synthetic SA may
contain impurities such as 4-hydroxybenzoic acid, 4-
hydroxyisophthalic acid and phenol. RP-HPLC methods
[22,23] for the assay in dermopharmaceutical forms [24]
and in an ointment product [25] have also been reported
(Fig. 1).
2.  Experimental
2.1.  Chemical  and  reagents
Deferasirox bulk drug obtained as gift sample from
Cadila Pharma, Ahmedabad. Salicylic acid, salicylamide
and Orthophosphoric acid were obtained from SD Fine-
Chem Limited. Acetonitrile (fisher Qualigens, HPLC
grade) were obtained from Thermo Fisher Scientific
India Pvt. Ltd. and potassium dihydrogen phosphate was
obtained from (Merck Specialties Private Limited).
2.2.  Equipments
Equipment Apparatus
HPLC system Dionex ultimate 3000 (Germany) high
performance liquid chromatographic system
equipped with ultimate 3000 pump, auto
sampler, column compartment and RS diode
array detector
Software Dionex Chromeleon® 7 (Version 7.1, simply
intelligent)
Column oven Ambient
Column Waters symmetry C18 (4.6 mm × 250 mm,
5 m, 110 A˚)iversity for Science 9 (2015) 245–251
2.3.  Preparation  of  buffer
Dissolved 1.36 g of potassium dihydrogen phosphate
in 1000 mL high purity demonized Milli-Q water (Milli-
pore, Milli-Q, Bedford, MA, USA, purification system)
and pH was adjusted 3.2 with ortho-phosphoric acid
and filtered through 0.22   size nylon filter under vac-
uum.
2.4.  Preparation  of  mobile  phase
The mobile phase was prepared by mixing 400 mL
phosphate buffer pH 3.2 and 600 mL of acetonitrile
(HPLC grade). The mixture was sonicated in Expo-Hi
Tech sonicator for 5 min.
2.5.  Preparation  of  diluent
Diluent for deferasirox is 99.5 mL acetonitrile and
0.5 mL water.
2.6.  Preparation  of  standard  and  sample  solution
The standard stock solutions were prepared by
accurately weighing 100 mg of each salicylamide, sal-
icylic acid and deferasirox in 100 mL volumetric flask
(1000 g/mL) in acetonitrile. Sample solutions were pre-
pared by appropriate dilution of the standard solutions
with the diluent.
3.  Result  and  discussion
3.1.  Method  development  and  optimization
To develop a precise, accurate and suitable RP-HPLC
method for the simultaneous estimation of salicylamide,
salicylic acid and deferasirox different mobile phases,
solvent–buffer ratios and pH were tried to proposedoped was unique in determining the impurities even at
low levels than that of specifications. The developed
method was successfully applied to estimate the amount
of deferasirox.
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.2.  Optimized  conditions
arameter Optimized condition
low rate 1.0 mL/min
obile phase 40:60 v/v (buffer: ACN)
uffer pH Potassium phosphate buffer pH 3.2
adjusted by OPA
avelength 245 nm
njection volume 10 l
un time 15 min
olumn and column oven
temperature
30 ◦C
.3.  Dosage  form  analysis
The proposed method was successfully applied to
he simultaneous determination of salicylamide, salicylic
cid and deferasirox in laboratory prepared mixtures and
n their combined bulk dosages forms. The average per-
ent recoveries of different concentrations were based on
he average of three replicate determinations (Table 3).
.  Validation  of  method
The optimized RP-HPLC assay method was validated
or specificity, linearity, accuracy, precision (repeatabil-
ty and intermediate precision), recovery and system
uitability according to International Conference on
armonization (ICH) guidelines for the validation of
ioanalytical method [26] and the US Food and Drug
dministration (FDA) [27].
.1.  Speciﬁcity
Specificity of method can be absence of any inter-
erence at retention times of samples. The specificity of
he method was demonstrated by injection of standard
olution of salicylamide, salicylic acid and deferasirox
t concentration of 100 g/mL. The elution peaks of
alicylamide, salicylic acid and deferasirox presented
n representative chromatograms shown in Fig. 2.
he representative chromatogram for simultaneouse, salicylic acid and deferasirox.
determination of the studied drugs in API pharmaceutical
dosages forms (Fig. 3).
4.2.  Linearity
The linearity of salicylamide, salicylic acid and
deferasirox were studied by preparing standard solu-
tion at five different concentrations ranging from 1.0 to
50.0 g/mL. Each concentration was injected in a five
replicates and mean value of peak area was taken for
calibration curve.
4.2.1.  Construction  of  the  calibration  curves
Working solutions containing (1.00–500.00) g/mL
were prepared by serial dilution of standard solution with
the acetonitrile. In all cases, 10 L aliquots were injected
(triplicate) and eluted with the mobile phase under
the following chromatographic conditions. The average
peak area ratio of each drug and the internal standard
were plotted versus the final concentration of the drug
in g/mL to get the calibration graph. Alternatively, the
corresponding regression equation was derived (Fig. 4
and Table 1).
4.3.  Precision
The precision of the assay was studied with respect to
both intra-day (Repeatability) and Inter-day (Intermedi-
ated) precisions. Repeatability was calculated from five
replicate injections of three different concentrations of
salicylamide, salicylic acid and deferasirox in the same
equipment on the same day. Inter day precision was
checked with the same concentrations as intra-day assay
and the determination of each compound was repeated
day by day during 3 days. The method was found to be
precise with RSD values within for intra-day and inter
day assay. Evaluation of the intra-day and inter-day pre-
cision for the determination of salicylamide, salicylic
acid and deferasirox by the proposed HPLC method
according to ICH guidelines (Table 2).
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Fig. 2. Optimized chromatogram of salicylamide, salicylic acid and deferasirox.
spectrumFig. 3. UV–visible 
4.4.  Limit  of  detection  (LOD)  and  limit  of
quantiﬁcation  (LOQ)
The limit of detection (LOD) is defined as the low-
est concentration of an analyte that can reliably be
differentiated from background levels. The standard
solutions of the compounds for LOD were prepared
by diluting them sequentially. Limit of quantification
Table 1
Summary of linearity data.
Sr. no. Parameters Salicylamide 
1 Linearity range (g/mL) 1.0–50.0 g/mL 
2 Slope ± standard error 0.3032 
3 Intercept ± standard error 0.0504x  
4 Linearity equation y = 0.3032x − 0.050
5 r2 0.9912  for spike sample.
(LOQ) of an individual analytical procedure is the lowest
amount of analyte that can be quantitatively determined
with suitable precision and accuracy. LOD and LOQ
were determined calculating the signal-to-noise ratio
of each compound by injecting a series of solution
until the S/N  ratio 3 for LOD and 10 for LOQ. where
S is the standard deviation of y-intercepts of regres-
sion.
Salicylic acid Deferasirox
1.0–50.0 g/mL 1.0–50.0 g/mL
0.1542 0.5735
0.1122x  1.0842x
4 y = 0.1542x  + 0.1122 y = 0.5735x + 1.0842
0.9989 0.9826
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Table 2
Intra-day and inter-day precision data.
Set no. Con. (g/mL) RT min. Intra day SD for intra day % RSD for intra day Inter day SD for inter day % RSD for inter day
SAL
500 2.867 99.90 0.020412 0.020433 99.91 0.046904 0.046946
100 2.867 99.96 0.015055 0.015061 99.95 0.016021 0.016029
50 2.867 99.95 0.018619 0.018628 99.94 0.038859 0.038884
SA
500 3.407 99.96 0.01633 0.016336 99.96 0.017607 0.017615
100 3.407 99.97 0.013663 0.013667 99.97 0.017224 0.017229
50 3.407 99.93 0.037639 0.037664 99.95 0.02137 0.021381
D
500 7.037 99.96 0.012111 0.012116 99.95 0.023664 0.023676
0.0187
0.0282
4
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9EF 100 7.037 99.95 0.018708 
50 7.037 99.95 0.028284 
.5.  Accuracy
Accuracy of the assay method was calculated for sal-
cylamide, salicylic acid and deferasirox by recovery
tudies at three concentrations of 50%, 100% and 150%
evels by standard addition method. The mean % recover-
es for salicylamide, salicylic acid and deferasirox were
ound to be 99.74%, 99.52% and 99.40% respectively
Table 3).
able 3
ccuracy data (three concentrations of 50%, 100% and 150% levels).
r. no. Sample Spike level Added (g/mL) Found (g/mL)
4.27 4.25 
 SAL 50 4.26 4.25 
4.25 4.25 
2.64 2.62 
 SA 50 2.65 2.62 
2.64 2.61 
2.5 2.49 
 DEF 50 2.53 2.49 
2.55 2.49 
11.28 11.26 
 SAL 100 11.3 11.26 
11.4 11.29 
10.1 10.13 
 SA 100 10.12 10.00 
10.13 10.03 
10.60 10.60 
 DEF 100 10.60 10.59 
10.59 10.60 
25.47 25.45 
 SAL 150 25.49 25.45 
25.48 25.48 
22.52 22.51 
 SA 150 22.49 22.49 
22.51 22.50 
23.87 23.85 
 DEF 150 23.89 23.86 
23.85 23.84 19 99.95 0.026394 0.026407
98 99.95 0.027869 0.027883
4.6.  System  suitability
System suitability was performed by using
100 g/mL of salicylamide, salicylic acid and
deferasirox by making six replicate injections.
Chromatographic parameters calculated from experi-
mental data, such as Number of theoretical plates, %
RSD of peak area and resolution factors (Rs) are given
in Table 4. The system was deemed to be suitable for
 % Recovery % Mean recovery SD % RSD
99.61
99.84 99.79 0.165025 0.165367
99.93
99.26
99.023 99.16 0.124925 0.125978
99.21
99.6
98.44 98.57 0.96692 0.980914
97.68
99.84
99.67 99.51 0.427122 0.429211
99.03
100.3
98.89 99.40 0.779252 0.783929
99.02
99.98
99.94 99.99 0.55678 0.55683
100.05
99.93
99.86 99.93 0.065064 0.065112
99.99
99.99
100.04 100.01 0.028868 0.028866
99.99
99.93
99.89 99.64 0.468081 0.469772
99.1
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Table 4
System suitability parameters.
Sr. no. Parameters Salicylamide Salicylic acid Deferasirox
1 Linearity range (g/mL) 1.0–50.0 g/mL 1.0–50.0 g/mL 1.0–50.0 g/mL
2 Retention time (min) 2.867 3.407 7.867
3 Theoretical plates (N) 12,153 4422 6814
4 Peak asymmetry (T) 1.26 3.20 2.47
5 Resolution (Rs) 3.0 < K′ < 20 5.0 < K′ < 20 5.0 < K′ < 20
6 Accuracy 99.51 99.40 99.99
7 Precision 99.96 
8 % RSD (for peak area) 0.79411 
Salicylic aci d 
Salicylamide
Deferasirox
0.293
2.774
6.783 8.415
11.6 74
15.549
y = 0.30 32x - 0.0504
R² = 0.99 120
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Area  Vs Con.Fig. 4. Linearity calibration curve of salicylamide, salicylic acid and
deferasirox.
use if the capacity factors were in the range of 2–20
(2 < K′ < 20), lower than 2 for tailing factor, more than
2 for resolution (Rs), greater than 2000 number of
theoretical plates (N), resolution between salicylamide,
salicylic acid and deferasirox of at least two and less99.93 99.95
0.089359 0.009275
than 2% relative standard deviation (% RSD) for peak
area.
5.  Conclusion
An accurate, sensitive, and precise RP-HPLC method
with PDA detection was developed and validated for
quality control analysis of salicylamide, salicylic acid
and deferasirox in their bulk API dosages forms. The
proposed method is very rapid, where the total analyti-
cal run time for three APIs and the internal standard is
less than 10 min. The method can also be readily adapted
to routine quality control analysis.
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